- L. Archibald-Pannone, J. Sevilleja, R. Guerrant.
Diarrhea, Clostridium difficile, and intestinal inflammation in residents of a long-term care facility.
2010. J Am Med Dir Assoc. 11 (4): 263-7
- J. Boone, L. Archibald-Pannone, K. Wickham, R. Carman, R. Guerrant, C. Franck, D. Lyerly.
Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality.
2014. Eur J Clin Microbial Infect Dis. 33 (6) 1045-51.
- J. Boone, J. DiPersio, M. Tan, S. Salstrom, K. Wickham, R. Carman, H. Totty, R. Albert, D. Lyerly.
Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infections.
2013. Eur J Clin Microbial Infect Dis. 32: 1517-1523
- P. LaSala, T. Eckhmimi, A. Hill, I. Farooqi, P. Perrotta.
Quantitative fecal lactoferrin in toxin-positive and toxin-negative Clostridium difficile specimens.
2012. J Clin Microbial. DOI: 10.1128/JCM.02735-12
- M. Wren, M. Sivapalan, R. Kinson, N. Shetty.
Laboratory diagnosis of Clostridium difficile infection. An evaluation of tests for faecal toxin, glutamate dehydrogenase, lactoferrin and toxigenic culture in the diagnostics laboratory.
2008. Br J Biomed Sci. 661 (1): 1-5
- S. Pawlowski, L. Archibald-Pannone, R. Carman, C. Alcantara-Warren, D. Lyerly, C. Genheimer, D. Gerding, R. Guerrant.
Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile.
2009. J Hosp Infect. 73 (2): 185-187
- R. El Feghaly, J. Stauber, E. Deych, C. Gonzalez, P. Tarr, D. Haslam.
Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection.
2013. Clinical Infectious Diseases 56 (12): 1713-2
Intestinal Inflammation Publications
- J. Däbritz, J. Musci, D. Foell.
Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome
2014. World Journal of Gastroenterol 20:2. 363-375.
- R. Sidhu, P. Wilson, A. Wright, C. Yau, F. D’Cruz, L. Foye, S. Morley, A. Lobo, M. Mcalindon, D. Sanders.
Faecal lactoferrin—a novel test to differentiate between the irritable and inflamed bowel?
2010. Alimentary Pharmacology & Therapeutics 31. 1365-1370
- T. Walker, M. Land, A. Kartashov, T. Saslowsky, D. Lyerly, J. Bonne, P. Rufo.
Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease (Subscription required to view full text)
2007. J Pediatr Gastroenterol Nutr 44:4. 414-422
- M. Parsi, B. Shen, J. Achkar, F. Remzi, J. Goldblum, J. Boone, D. Lin, J. Connor, V. Fazio, B. Lashner.
Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch- anal anastomosis
2004. Gastroenterology 126. 1280-1286.
- S. Kane, W. Sandborn, P. Rufo, A. Zholudev, J. Boone, D. Lyerly, M. Camilleri, S. Hanauer.
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. (Purchase required to view full text)
2003. Am J Gastroenterol 98:6. 1309-1314.
- G. Van Assch, S. Hanauer
Fecal biomarkers for the diagnosis and management of inflammatory bowel disease. (Purchase required to view full text)
2011. Gastro and Hep 7:6. 396-398.
- B. Abraham, S. Kane.
Fecal markers: calprotectin and lactoferrin. (Purchase required to view full text)
2013. Gastroenterol Clin N Am. 41. 483-495.
- Boone JH, Archbald‐Pannone LR, Wickham KN, Carman RJ, Guerrant RL, Franck CT, Lyerly DM, 2014. Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality. Eur J Clin Microbiol Infect Dis. Published online.
- Boone JH, DiPersio JR, Tan MJ, Salstrom SJ, Wickham KN, Carman RJ, Totty HR, Albert RE, and Lyerly DM, 2013. Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection. Eur J Clin Microbiol Infect Dis. 32:1517‐1523.
- Hall IC, O’Toole E, 1935. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Childhood. 49: 390‐402.
- Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E et al, 2007. A portrait of the geographic dissemination of the Clostridium difficile North American pulse‐field type 1 strain and the epidemiology of C. difficile‐associated disease in Québec. Clin Infect Dis. 44:238‐244.
- LaSala PR, Ekhmimi T, Hill AK, Farooqi I, Perrotta PL, 2012. Quantitative fecal lactoferrin in toxin‐positive and toxin‐negative Clostridium difficile specimens. J Clin Micrbiol. 51 (1): 311‐313.
- Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S et al, 2005. A predominantly clonal multi‐ institutional outbreak of Clostridium difficile‐ associated diarrhea with high morbidity and mortality. N Engl J Med. 352: 2442‐2449.
- McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP et al, 2005. An epidemic, toxin gene‐variant strain of Clostridium difficile. N Engl J Med 353:2433‐2441.
- Ribotype 027 is Associated with Increased Lactoferrin and Toxin in Patients with Clinically Defined C. difficile Disease
American Society of Microbiology meeting, May 2011, New Orleans, LA
- Evaluation of Fecal Lactoferrin, CRP and Clinical Activity Indices for Assessing the Presence of Intestinal Inflammation in IBD and IBS Patients Classified by Ileocolonoscopy
- Comparison of CRP, Clinical Activity Indices and Fecal Lactoferrin with Disease Status in Ileocolonoscopy of Patients with IBD and IBS
Digestive Disease Week, May 2006, Los Angeles, CA
- A Comparison Among Four Neutrophil-Derived Proteins in Feces as Indicator of Disease Activity in Ulcerative Colitis
Digestive Disease Week, May 2004, New Orleans, LA
- Serial Fecal Lactoferrin Measurements are Useful in the Interval Assessment of Patients with Active and Inactive Inflammatory Bowel Disease
Digestive Disease Week, May 2004, New Orleans, LA
- Fecal Lactoferrin: Sensitive Marker for Monitoring Pediatric Patients with Inflammatory Bowel Disease (IBD)
Digestive Disease Week, May 2003, Orlando, FL
LEUKO EZ VUE®
- Boone JH, 2010. Determining Severity for Patients with C. difficile Disease. TECHLAB Diarrhea Digest. Spring, 6‐8.